SHP-1

AcronymDefinition
SHP-1Anti-Src Homology Phosphatase-1
SHP-1Src (Sarcoma) Homology 2 Domain Phosphatase-1 (tyrosine phosphatase)
References in periodicals archive ?
We'll need an inhibitor of SHP-1 together with antioxidants to have a realistic chance of preventing or stopping diabetic eye disease," said King.
We think this is also applicable to diabetic kidney disease, because we observed a similar increase in SHP-1 in the kidneys of diabetic animals," he added.
VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits Akt, a member of the serine/threonine-specific protein kinase family that is amplified, overexpressed, and/or activated in prostate, breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases SHP-1, SHP-2, and PTP1B that has demonstrated clinical and biological activity in solid tumors; and Xyfid(TM), a topical therapy which is being developed for the treatment and prevention of chemotherapy-induced Hand-Foot Syndrome (HFS).
Lenocta (sodium stibogluconate) is a selective, small molecule inhibitor of certain protein tyrosine phosphatases (PTPs), such as SHP-1, SHP-2 and PTP1B, with demonstrated anti-tumor activity against a wide spectrum of cancers both alone and in combination with other approved immune activation agents, including IL-2 and interferons.
VioQuest's oncology portfolio includes: Xyfid[TM] (1% uracil topical), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta[TM] (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B.
VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits activation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases (PTPases), SHP-1 and SHP-2, which has shown compelling clinical and biological activity in solid tumors and Xyfid(TM), a topical therapy which has shown early clinical promise in the treatment and prevention of chemo-induced Hand-Foot Syndrome (HFS).